» Articles » PMID: 7888188

The World Health Organization Global Programme on AIDS Proposal for Standardization of HIV Sequence Nomenclature. WHO Network for HIV Isolation and Characterization

Overview
Publisher Mary Ann Liebert
Date 1994 Nov 1
PMID 7888188
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The World Health Organization Global Programme on AIDS (WHO/GPA) is conducting a large-scale collaborative study of human immunodeficiency virus type 1 (HIV-1) variation, based in four potential vaccine-trial site countries: Brazil, Rwanda, Thailand, and Uganda. Through the course of this study, it was crucial to keep track of certain attributes of the samples from which the viral nucleotide sequences were derived (e.g., country of origin and viral culture characterization), so that meaningful sequence comparisons could be made. Here we describe a system developed in the context of the WHO/GPA study that summarizes such critical attributes by representing them as standardized characters directly incorporated into sequence names. This nomenclature allows linkage of clinical, phenotypic, and geographic information with molecular data. We propose that other investigators involved in human immunodeficiency virus (HIV) nucleotide sequencing efforts adopt a similar standardized sequence nomenclature to facilitate cross-study sequence comparison. HIV sequence data are being generated at an ever-increasing rate; directly coupled to this increase is our deepening understanding of biological parameters that influence or result from sequence variability. A standardized sequence nomenclature that includes relevant biological information would enable researchers to better utilize the growing body of sequence data, and enhance their ability to interpret the biological implications of their own data through facilitating comparisons with previously published work.

Citing Articles

Development of a contemporary globally diverse HIV viral panel by the EQAPOL program.

Sanchez A, DeMarco C, Hora B, Keinonen S, Chen Y, Brinkley C J Immunol Methods. 2014; 409:117-30.

PMID: 24447533 PMC: 4104154. DOI: 10.1016/j.jim.2014.01.004.


A single-nucleotide synonymous mutation in the gag gene controlling human immunodeficiency virus type 1 virion production.

Hamano T, Matsuo K, Hibi Y, Victoriano A, Takahashi N, Mabuchi Y J Virol. 2006; 81(3):1528-33.

PMID: 17121798 PMC: 1797536. DOI: 10.1128/JVI.01596-06.


Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.

Yang X, Kurteva S, Ren X, Lee S, Sodroski J J Virol. 2005; 79(19):12132-47.

PMID: 16160141 PMC: 1211524. DOI: 10.1128/JVI.79.19.12132-12147.2005.


Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.

Scordi-Bello I, Mosoian A, He C, Chen Y, Cheng Y, Jarvis G Antimicrob Agents Chemother. 2005; 49(9):3607-15.

PMID: 16127029 PMC: 1195443. DOI: 10.1128/AAC.49.9.3607-3615.2005.


Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates.

Hunt G, Papathanasopoulos M, Gray G, Tiemessen C Virus Genes. 2003; 26(1):49-56.

PMID: 12680693 DOI: 10.1023/a:1022378022104.